The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects
The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects
复制标题
DOI：
10.1111/j.1651-2227.2010.01933.x
复制
发表时间：
2010-12-01
期刊：
影响因子：
3.8
通讯作者：
Ben-Ari, Yehezkel
中科院分区：
文献类型：
--
作者：
Lemonnier, Eric;Ben-Ari, Yehezkel
抑制性递质 GABA 已被认为在婴儿自闭症候群 (IAS) 中发挥重要作用，广泛的研究表明 GABA 在神经系统疾病中的兴奋作用是由于 [Cl(-)](I) 持续增加所致。目的：测试氯协同转运蛋白 NKCC1 利尿化合物布美他尼 (Bumetanide) 对 IAS 的作用，该化合物可减少 [Cl(-)](I)。方法：布美他尼每天给药（1 mg）每天）在 3 个月期间进行临床和生物学测试。我们使用了 5 个标准 IAS 严重性测试 - 儿童自闭症评定量表、异常行为检查表、临床总体印象；重复性和限制性行为以及调节障碍评估表。结果：我们报告了 IAS 的显着改善，且无副作用。结论：布美他尼可减少自闭症行为，且无副作用，表明利尿剂可能对 IAS 产生有益作用，并且改变 GABA 的作用可能对 IAS 治疗有效，需要进行大规模随机试验。
The inhibitory transmitter GABA has been suggested to play an important role in infantile autistic syndrome (IAS), and extensive investigations suggest that excitatory actions of GABA in neurological disorders are because of a persistent increase of [Cl(-)](I).Aims: To test the effects of the chloride co-transporter NKCC1 diuretic compound Bumetanide that reduces [Cl(-)](I) on IAS.Methods: Bumetanide was administered daily (1 mg daily) during a 3 -month period and clinical and biological tests made. We used 5 standard IAS severity tests - Childhood Autism Rating Scale, Aberrant Behaviour Checklist, Clinical Global Impressions; Repetitive and Restrictive Behaviour and the Regulation Disorder Evaluation Grid.Results: We report a significant improvement in IAS with no side effects.Conclusion: Bumetanide decreases autistic behaviour with no side effects suggesting that diuretic agents may exert beneficial effects on IAS and that alterations of the actions of GABA may be efficient in IAS treatment calling for large scale randomized trials.